Passage Bio Inc

-0.06 (-5.17%)
7:04:35 PM EDT: $1.15 +0.05 (+4.55%)
Layoffs, Earnings Announcements

Passage Bio Reports Q3 2022 Financial Results

Published: 11/10/2022 12:47 GMT
Passage Bio Inc (PASG) - Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates.
Q3 Loss per Share $0.49.
Passage Bio - Company to Streamline Operations and Refocus Strategy.
Passage Bio - Advancing Imagine-1 Clinical Trial for Gm1 Gangliosidosis,uplift-d Clinical Trial for Frontotemporal Dementia.
Advancing Preclinical Pipeline in Adult Cns Indications.
Cash Runway Extended Into 1h 2025.
Will Decrease Operating Expenses by Reducing Workforce by About 23 Percent and Prioritizing Research and Development Investments.
Will Stop Further Clinical Development of Pbkr03 for Krabbe Disease and Explore Strategic Alternatives to Advance This Program.
Will Explore Strategic Alternatives to Advance Program for Metachromatic Leukodystrophy, Pbml04.
Passage Bio - to Prioritize Advancing Programs for Amyotrophic Lateral Sclerosis & Huntington's Disease.
Qtrly Net Loss per Share of Common Stock, Basic and Diluted $0.49.
Q3 Earnings per Share View $-0.79 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.52

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.52

More details on our Analysts Page.